Creative Medical Technology Holdings Highlights 93% Patient Response Rate and 65% Reduction in Average Pain Scores in Ultrasome™ Knee Osteoarthritis StudyGlobeNewsWire · 4 days ago
Head to Head Analysis: Creative Medical Technology (NASDAQ:CELZ) versus Grifols (NASDAQ:GRFS)Defense World · Sep 30, 2026
Creative Medical Technology (NASDAQ:CELZ) & argenex (NASDAQ:ARGX) Head to Head AnalysisDefense World · Sep 25, 2026
Creative Medical Technology Holdings, Inc. Expands Ultrasome™ Intellectual Property Portfolio with New U.S. Provisional Patent FilingGlobeNewsWire · Sep 17, 2026
Critical Contrast: Creative Medical Technology (NASDAQ:CELZ) vs. CRISPR Therapeutics (NASDAQ:CRSP)Defense World · Sep 8, 2026
Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 PlanningGlobeNewsWire · Aug 20, 2026Creative Medical Technology Holdings, Inc., a biotechnology firm based in Phoenix, Arizona, specializes in advancing adult stem cell treatments. The company's core focus spans several medical fields, including immunology, urology, orthopedics, and neurology. Among its therapeutic offerings are CaverStem, designed to address erectile dysfunction; FemCelz, which aims to restore genital sensitivity and alleviate dryness; StemSpine, developed to treat chronic lower back pain; ImmCelz, intended for stroke patients; and OvaStem, a solution for female infertility.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 7, 2026 | -$0.39 | -$0.41 | Miss |
| May 8, 2026 | -$0.39 | -$0.38 | Beat |
| Mar 20, 2026 | -$0.37 | -$0.80 | Miss |
| Nov 7, 2025 | -$0.48 | -$0.48 | Beat |
| Aug 8, 2025 | -$0.63 | -$0.48 | Beat |
| May 9, 2025 | -$0.52 | -$0.83 | Miss |